STRATEC SE

M&A Activity • Jan 25, 2006

News Details

Corporate | 25 January 2006 14:34

STRATEC and CyBio sign sales cooperation agreement

Corporate-news transmitted by DGAP. The issuer is solely responsible for the content of this announcement. —————————————————————————— STRATEC and CyBio sign sales cooperation agreement STRATEC expands its shareholding in CyBio Birkenfeld/Jena, January 25, 2006 On January 23, 2006, CyBio AG, Jena, and STRATEC Biomedical Systems AG, Birkenfeld, signed a cooperation agreement at “LabAutomation”, one of the most important laboratory automation fairs, in Palm Springs, California, USA. The object of this contractual agreement is the non-exclusive sale by CyBio of systems of STRATEC’s “Robion” brand. These systems are being designed and manufactured by STRATEC for the pharmaceutical and biotechnology sector and will be sold worldwide by CyBio under its own name. The fully automated systems designed and manufactured by STRATEC will initially supplement CyBio’s liquid handling portfolio with a flexible pipetting platform, thus expanding CyBio’s range of applications for the life science industry. This cooperation will enable STRATEC to benefit from CyBio’s established global sales network and will thus save it from having to build up its own costly sales organization. In view of this development, on January 20, 2006 STRATEC Biomedical Systems AG increased its existing shareholding in its new sales partner, CyBio, by 6.250% from 4.875% to 11.125% by means of an off-market transfer placement. About CyBio CyBio AG ( http://www.cybio-ag.com ; ISIN: DE0005412308), with its principal headquarters in Jena, Germany, and sales subsidiaries in Europe and the USA, is a globally active life science company. As an innovative technology company, CyBio develops, produces and sells technology platforms used in drug discovery. With more than 15 years of experience, CyBio’s hardware, software and service products have set new standards in terms of their precision, speed and engineering output in the field of automated drug discovery. The product portfolio consists of a wide range of pharmaceutical and agrochemical research solutions: liquid handling, detection, software and system integration, in order to create fully automated screening technologies holding the key to innovative and efficient high-throughput drug discovery. About STRATEC STRATEC Biomedical Systems AG ( http://www.stratec-biomedical.de ) designs and manufactures fully automated systems for its partners in the fields of clinical diagnostics and biotechnology. These partners market such systems, in general together with their own reagents, to laboratories and research institutes around the world. The company develops its products on the basis of its own patented technologies. Shares in the company (ISIN: DE0007289001) are traded in the Prime Standard segment of the Frankfurt Stock Exchange, in the Gate-M trading segment of the Stuttgart Stock Exchange and on other exchanges. The STRATEC Group comprises the listed holding company “STRATEC Biomedical Systems AG”, as well as the wholly-owned subsidiaries “STRATEC NewGen GmbH” and “Robion AG”. For further information, please contact: STRATEC Biomedical Systems AG André Loy, Investor Relations Gewerbestrasse 37, 75217 Birkenfeld Germany Tel: +49 (0)7082 7916 190 Fax: +49 (0)7082 7916 999 E-Mail: ir@stratec-biomedical.de CyBio AG Franziska Haase, Investor Relations Goeschwitzer Strasse 40, 07745 Jena Germany Tel: +49 (0)3641 351 401 Fax: +49 (0)3641 351 409 E-Mail: franziska.haase@cybio-ag.com End of announcement (c)DGAP 25.01.2006 —————————————————————————— WKN: 728900; ISIN: DE0007289001; Index: Listed: Geregelter Markt in Frankfurt (Prime Standard) und Stuttgart (Gate-M); Freiverkehr in Berlin-Bremen, Düsseldorf und München